Intersect ENT Inc., located in Menlo Park, Calif., is an innovator in local drug delivery focused on advancing clinically proven therapy solutions that improve quality of life for patients with ear, nose and throat conditions. The company's initial products, the PROPEL and PROPEL mini dissolvable steroid-releasing implants, are the only products backed by Level 1-A clinical evidence to improve sinus surgery outcomes for patients suffering from chronic sinusitis.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/25/13 | $30,000,000 | Series D |
Medtronic PTV Sciences U.S. Venture Partners | undisclosed |
